MedKoo Biosciences

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

 

 

 


 

Back to products

 

 

Browse products

Approved anticancer agents

Anticancer agents in trials

Anticancer agents in preclinical trials

Anticancer molecular libraries

 


Other drug agents

Drug intermediates

Bio-reagents and biochemicals

 

 


 

 

 

 

 

 

MedKoo product information:

 Granisetron hydrochloride

  

Description of granisetron hydrochloride:  granisetron hydrochloride is the hydrochloride salt of an indazole derivative with antiemetic properties. As a selective serotonin receptor antagonist, granisetron competitively blocks the action of serotonin at 5-hydroxytryptamine3 (5-HT3) receptors, resulting in the suppression of chemotherapy- and radiotherapy-induced nausea and vomiting. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

  

MedKoo Cat#:  100421

Name:  Granisetron hydrochloride

CAS#:  107007-99-8 ( Granisetron hydrochloride); 109889-09-0 ( Granisetron)

 

Synonym:  US brand name: Kytril; Abbreviation: GRAN.

   

IUPAC/Chemical name:

1-methyl-N-((1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)-1H-indazole-3-carboxamide hydrochloride

   

Chemical structure:

Theoretical analysis :

 

Granisetron HCl structure

 

MedKoo Cat#: 100421
Name:  Granisetron hydrochloride
CAS#:  107007-99-8

Chemical Formula: C18H25ClN4O

Molecular Weight: 348.87

Elemental Analysis: C, 61.97; H, 7.22; Cl, 10.16; N, 16.06; O, 4.59

 

Granisetron

Chemical Formula: C18H24N4O

Exact Mass: 312.19501

Molecular Weight: 312.41

Elemental Analysis: C, 69.20; H, 7.74; N, 17.93; O, 5.12

      

   

Availability and price:

Granisetron hydrochloride (99%)  is in stock. Current delivery time is overnight (USA/Canada) or 3-5 days (international). Price and availability confirmed on 11/16/2013. Shipping cost: $30.00 (USA); $45.00 (Canada); $70.00 (international).

50mg / $70.00

100mg / $120.00

200mg / $150.00

500mg / $250.00

1.0g / $320.00

2.0g / $390.00

5.0g / $550.00

10.0g / $950.00

20.0g / $1,550.00

Bulk available at low price.  

YYP#20131023#$^^&*10++^**208;&&*(20@#$%320 #$%

For quotation, question, and order, please send email to sales@medkoo.com to describe your needs. A representative will respond your email shortly. We offer significant discount for larger quantity order.

 

Quality control data:

Product will be shipped with supporting analytical data.

 

 

Information about this agent

 

 

According to http://en.wikipedia.org/wiki/Granisetron, Granisetron was developed by chemists working at the British drug company Beecham around 1988 and is available as a generic. It is produced by Roche Laboratories under the trade name Kytril. The drug was approved in the United Kingdom in 1991 and in United States in 1994 by the FDA. A granisetron transdermal patch with the trade name Sancuso was approved by the US FDA on September 12, 2008. Sancuso is manufactured by ProStrakan, Inc., a pharmaceutical company headquartered in Bedminster, NJ, with global headquarters in Scotland. Granisetron breaks down slowly, staying in the body for a long time. One dose usually lasts 4 to 9 hours and is usually administered once or twice daily. This drug is removed from the body by the liver and kidneys.

 

DRUG DESCRIPTION

KYTRIL Tablets and KYTRIL Oral Solution contain granisetron hydrochloride, an antinauseant and antiemetic agent. Chemically it is endo-N-(9-methyl-9-azabicyclo [3.3.1] non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride with a molecular weight of 348.9 (312.4 free base). Its empirical formula is C18H24N4OHCl. Granisetron hydrochloride is a white to off-white solid that is readily soluble in water and normal saline at 20C.

 

Tablets for Oral Administration: Each white, triangular, biconvex, film-coated KYTRIL Tablet contains 1.12 mg granisetron hydrochloride equivalent to granisetron, 1 mg. Inactive ingredients are: hydroxypropyl methylcellulose, lactose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, sodium starch glycolate, and titanium dioxide.

Oral Solution: Each 10 mL of clear, orange-colored, orange-flavored KYTRIL Oral Solution contains 2.24 mg of granisetron hydrochloride equivalent to 2 mg granisetron. Inactive ingredients: citric acid anhydrous, FD&C Yellow No. 6, orange flavor, purified water, sodium benzoate, and sorbitol.

 

CLINICAL PHARMACOLOGY

Granisetron is a selective 5-hydroxytryptamine3 (5-HT3) receptor antagonist with little or no affinity for other serotonin receptors, including 5-HT1; 5-HT1A; 5-HT1B/C; 5-HT2; for alpha1-, alpha2-, or beta-adrenoreceptors; for dopamine-D2; or for histamine-H1; benzodiazepine; picrotoxin or opioid receptors. Serotonin receptors of the 5-HT3 type are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. During chemotherapy that induces vomiting, mucosal enterochromaffin cells release serotonin, which stimulates 5-HT3 receptors. This evokes vagal afferent discharge, inducing vomiting. Animal studies demonstrate that, in binding to 5-HT3 receptors, granisetron blocks serotonin stimulation and subsequent vomiting after emetogenic stimuli such as cisplatin. In the ferret animal model, a single granisetron injection prevented vomiting due to high-dose cisplatin or arrested vomiting within 5 to 30 seconds. In most human studies, granisetron has had little effect on blood pressure, heart rate or ECG. No evidence of an effect on plasma prolactin or aldosterone concentrations has been found in other studies.

Following single and multiple oral doses, KYTRIL Tablets slowed colonic transit in normal volunteers. However, KYTRIL had no effect on oro-cecal transit time in normal volunteers when given as a single intravenous (IV) infusion of 50 mcg/kg or 200 mcg/kg.

 

References

1: Wu SJ, Xiong XZ, Lin YX, Cheng NS. Comparison of the efficacy of ondansetron and granisetron to prevent postoperative nausea and vomiting after laparoscopic cholecystectomy: a systematic review and meta-analysis. Surg Laparosc Endosc Percutan Tech. 2013 Feb;23(1):79-87. doi: 10.1097/SLE.0b013e31827549e8. Review. PubMed PMID: 23386158.

2: Hsu ES. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics. Am J Ther. 2010 Sep-Oct;17(5):476-86. doi: 10.1097/MJT.0b013e3181ea7821. Review. PubMed PMID: 20844345.

3: Duggan ST, Curran MP. Transdermal granisetron. Drugs. 2009;69(18):2597-605. doi: 10.2165/11202780-000000000-00000. Review. PubMed PMID: 19943709.

4: Vrabel M. Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials. Clin J Oncol Nurs. 2007 Dec;11(6):809-13. Review. PubMed PMID: 18063539.

5: Feyer P, Seegenschmiedt MH, Steingraeber M. Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies. Support Care Cancer. 2005 Sep;13(9):671-8. Epub 2005 Jul 26. Review. PubMed PMID: 16044252.

6: Aapro M. Granisetron: an update on its clinical use in the management of nausea and vomiting. Oncologist. 2004;9(6):673-86. Review. PubMed PMID: 15561811.

7: Goldsmith B. First choice for radiation-induced nausea and vomiting--the efficacy and safety of granisetron. Acta Oncol. 2004 Sep;43 Suppl 15:19-22. Review. PubMed PMID: 15370626.

8: Corman SL, Skledar SJ, Ansani NT. Low-dose granisetron for postoperative nausea and vomiting prophylaxis. Ann Pharmacother. 2004 Apr;38(4):710-3. Epub 2004 Feb 24. Review. PubMed PMID: 14982978.

9: Tan M. Granisetron: new insights into its use for the treatment of chemotherapy-induced nausea and vomiting. Expert Opin Pharmacother. 2003 Sep;4(9):1563-71. Review. PubMed PMID: 12943486.

10: Blum RA, Majumdar A, McCrea J, Busillo J, Orlowski LH, Panebianco D, Hesney M, Petty KJ, Goldberg MR, Murphy MG, Gottesdiener KM, Hustad CM, Lates C, Kraft WK, Van Buren S, Waldman SA, Greenberg HE. Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther. 2003 May;25(5):1407-19. Review. PubMed PMID: 12867217.

     

 

 

Contact MedKoo:

Email: sales@medkoo.com

 

(Keyword; CAS#; MedKoo Cat#)

 

 

 

 

 

 

 

About us  |  Services  |  Products  |  News  |  Careers  |  Contact us

MedKoo Biosciences. All Rights Reserved